We believe pharma and device companies make a huge difference in human lives. We believe patient/physician relationship should be based on 100% trust. Therefore, We believe and support global transparency movement. Our solutions make compliance with transparency and other regulations a welcome breeze.
View, monitor and analyze all your compliance data in one place.
Multichannel solution to better manage consent, disputes and pre-disclosure review.
Market and competitor intelligence at your fingertips.
What spend are you going to report under Sunshine Payments or EFPIA? Do you know what is in your data?
What will a journalist conclude when they access your public spend records? What will the OIG find as they look for co-relation in spend and Med Part D data under their 2017 work plan?
Let qordata Compliance Insights give you visibility into your own spend. It’s the kind of visibility the CMS/DOJ world wish for.
The latest Pharmaceutical Compliance, Transparency and Analytics insights from around the world, now at your fingertips. Get expert solutions to your specific Pharma Spend Issues.SIGN UP AS AN EXPERT
Efficiency and Foresight: The qordata Advantage For Zimmer Biomet
For Zimmer Biomet, Compliance Insights, a dedicated CMS Open Payments Solution, was an affirmative response to both. Within a short period, Zimmer Biomet recorded 50% cost reduction and a corresponding error rate reduction. It achieved quantifiable savings in time, efficiency, and gained better insights.DOWNLOAD
Helping thousands of people and companies communicate and work better.
qordata Releases Open Payments Data 2016
Princeton, New Jersey: qordata has released Open Payments Data 2016 less than 24 hours after the publication of 11.96 million financial transactions, (US $ value 8.18 billion) on the CMS Website.READ FULL STORY
Thought Leadership —Transparency, Insights And Disclosure
The approach towards data privacy in EU makes consideration towards consent revocation an imperative. If a physician revokes consent, individual versus aggregate spend figures need to be recalculated, and they will show the corresponding changes. Thus, historical consent rate figures may not be an accurate indicator of transparency in that specific market, or even attitude shifts towards transparency. Interest groups that don’t examine consent from this angle tend to make hasty judgments on transparency. The fourth estate is a repeat offender, often citing (or misrepresenting) published data as a way of drawing public attention to “Big Pharma’s Big Money.” Not only does this present a distorted view of pharmaceutical spend activity to the public, but it also discourages relatively open […]
Physician consent can be a contentious issue. Especially when data privacy interpretation comes into play. In a webinar we hosted, Brian Sharkey, VP of Porzio Life Sciences LLC raised a question about the validity of consent rates as an indicator of pharmaceutical transparency. So, is there a direct correlation between transparency in the pharmaceutical sector and physicians’ attitudes towards consent? Let data give the answers. How Are You Calculating Physician Consent? As we demonstrated in a webinar last year, the answer to ‘what is physician consent rate?’ can differ substantially depending on how you proceed with the consent calculation process. Some medical drug/device companies will calculate consent based on TOV amount. Hypothetically speaking, […]
How stringent are pharmaceutical disclosure requirements in your country? Depends on who you’re asking. Team qordata invited Brian Sharkey Vice President, Porzio Life Sciences LLC, to host our webinar on “EFPIA Reporting and Consent Management”. What he had to say pretty much confirms that when it comes to compliance disclosure, context is key. Some Measures Go Up, Some Go Down Did anticipated publication match actual publication rates in pharmaceutical spend for 2015 data? Not quite. Switzerland, at 72% was the only country in the EFPIA region where estimated consent equated to actual consent rate. Only three countries, the UK, Italy and Norway experienced the receipt of consent rates which exceeded their estimates; though the difference was marginal (not more than […]